ALAMEDA, Calif.--(BUSINESS WIRE)--May 23, 2017--
BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company
developing and commercializing products addressing degenerative
diseases, today announced that Co-Chief Executive Officer Michael D.
West, Ph.D., is delivering a presentation as part of a panel on
biotechnology at the Mauldin Economics’ Strategic Investment Conference
on Wednesday, May 24 at 3:20pm EDT at the Omni
Orlando Resort in Florida.
In his presentation, "Emerging Trends in Regenerative Medicine and
Aging,” Dr. West will provide an update on product development by the
BioTime group of companies, focusing on the strategy of transplanting
young healthy cells into tissues afflicted with age-related degenerative
disease. He will also discuss new products planned for development at
new subsidiary, AgeX Therapeutics.
More information about Mauldin Economics’ Strategic Investment
Conference can be found here.
BioTime is a clinical-stage biotechnology company focused on developing
and commercializing products addressing degenerative diseases. Our
clinical programs are based on two platform technologies: pluripotent
stem cells and cell/drug delivery platform technologies. The foundation
of our core therapeutic technology platform is pluripotent cells that
are capable of becoming any of the cell types in the human body. The
foundation of our cell delivery platform is its HyStem® cell and drug
delivery matrix technology. The Company’s current clinical programs are
targeting three primary sectors, aesthetics, ophthalmology and cell/drug
delivery. We also have significant equity holdings in two publicly
traded companies, Asterias Biotherapeutics, Inc. (“Asterias”) and
OncoCyte Corporation (“OncoCyte”), which we founded and which, until
recently, were our majority-owned consolidated subsidiaries.
BioTime common stock is traded on the NYSE MKT and TASE under the symbol
BTX. For more information, please visit www.biotimeinc.com
or connect with the company on Twitter,
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://news.biotimeinc.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170523006289/en/
Source: BioTime, Inc.
EVC Group, Inc.
Michael Polyviou, 212-850-6020
Bill Douglass, 646-504-0890